Cargando…
Systemic and local evidence for complement involvement in chronic spontaneous urticaria
BACKGROUND: The pathogenesis of chronic spontaneous urticaria (CSU), including the mechanism of action of omalizumab, remain unclear. We hypothesized complement system involvement given the often fast clinical response induced by treatment, including omalizumab. Therefore, we assessed the role of va...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254579/ https://www.ncbi.nlm.nih.gov/pubmed/34262691 http://dx.doi.org/10.1002/clt2.12011 |
_version_ | 1783717757190144000 |
---|---|
author | Alizadeh Aghdam, Mehran van den Elzen, Mignon van Os‐Medendorp, Harmieke van Dijk, Marijke R. Knol, Edward F. Knulst, André C. Röckmann, Heike Otten, Henny G. |
author_facet | Alizadeh Aghdam, Mehran van den Elzen, Mignon van Os‐Medendorp, Harmieke van Dijk, Marijke R. Knol, Edward F. Knulst, André C. Röckmann, Heike Otten, Henny G. |
author_sort | Alizadeh Aghdam, Mehran |
collection | PubMed |
description | BACKGROUND: The pathogenesis of chronic spontaneous urticaria (CSU), including the mechanism of action of omalizumab, remain unclear. We hypothesized complement system involvement given the often fast clinical response induced by treatment, including omalizumab. Therefore, we assessed the role of various complement factors surrounding omalizumab treatment. METHODS: Thirty CSU patients (median age 42 [range 21–70]; 73 % female) with a median once daily Urticaria Activity Score over 7 days (UAS7) score at baseline of 31.5 points were enrolled. Treatment consisted of six administrations of 300 mg omalizumab every 4 weeks succeeded by a follow‐up period of 12 weeks. Four punch skin biopsies were taken per patient; at baseline from lesional skin, at baseline from nonlesional skin, and after 1 and 7 days from formerly lesional skin. Complement activity, including C1q, C3, C3bc/C3, C4, C4bc/C4, C5a, and Membrane Attack Complex in peripheral blood were analyzed and complement activation in the skin was determined by the analysis of C4d deposition. Results were related to the clinical response to omalizumab. RESULTS: Fifteen patients showed a UAS7 score of 6 or lower (median 0) at Week 24, 15 patients did not (median 16). Lesional skin biopsies at baseline revealed complement deposition (C4d) in blood vessels in the papillary dermis of 53% (16/30) of the patients, which suggests involvement of immune complexes in the pathogenesis of urticaria. Moreover, indication of increased complement activation in CSU was substantiated by increased C5a levels in peripheral blood compared to healthy controls (p = 0.010). The clinical effect of omalizumab could not be linked to the variation of complement components. CONCLUSIONS: Both C4d deposition in lesional skin and elevated C5a levels in peripheral blood indicate the involvement of complement activation in the pathogenesis of CSU. No correlation was found between omalizumab and activation of complement indicative of independent processes in the immunopathogenesis of CSU. |
format | Online Article Text |
id | pubmed-8254579 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82545792021-07-13 Systemic and local evidence for complement involvement in chronic spontaneous urticaria Alizadeh Aghdam, Mehran van den Elzen, Mignon van Os‐Medendorp, Harmieke van Dijk, Marijke R. Knol, Edward F. Knulst, André C. Röckmann, Heike Otten, Henny G. Clin Transl Allergy Research BACKGROUND: The pathogenesis of chronic spontaneous urticaria (CSU), including the mechanism of action of omalizumab, remain unclear. We hypothesized complement system involvement given the often fast clinical response induced by treatment, including omalizumab. Therefore, we assessed the role of various complement factors surrounding omalizumab treatment. METHODS: Thirty CSU patients (median age 42 [range 21–70]; 73 % female) with a median once daily Urticaria Activity Score over 7 days (UAS7) score at baseline of 31.5 points were enrolled. Treatment consisted of six administrations of 300 mg omalizumab every 4 weeks succeeded by a follow‐up period of 12 weeks. Four punch skin biopsies were taken per patient; at baseline from lesional skin, at baseline from nonlesional skin, and after 1 and 7 days from formerly lesional skin. Complement activity, including C1q, C3, C3bc/C3, C4, C4bc/C4, C5a, and Membrane Attack Complex in peripheral blood were analyzed and complement activation in the skin was determined by the analysis of C4d deposition. Results were related to the clinical response to omalizumab. RESULTS: Fifteen patients showed a UAS7 score of 6 or lower (median 0) at Week 24, 15 patients did not (median 16). Lesional skin biopsies at baseline revealed complement deposition (C4d) in blood vessels in the papillary dermis of 53% (16/30) of the patients, which suggests involvement of immune complexes in the pathogenesis of urticaria. Moreover, indication of increased complement activation in CSU was substantiated by increased C5a levels in peripheral blood compared to healthy controls (p = 0.010). The clinical effect of omalizumab could not be linked to the variation of complement components. CONCLUSIONS: Both C4d deposition in lesional skin and elevated C5a levels in peripheral blood indicate the involvement of complement activation in the pathogenesis of CSU. No correlation was found between omalizumab and activation of complement indicative of independent processes in the immunopathogenesis of CSU. John Wiley and Sons Inc. 2021-07-03 /pmc/articles/PMC8254579/ /pubmed/34262691 http://dx.doi.org/10.1002/clt2.12011 Text en © 2021 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Alizadeh Aghdam, Mehran van den Elzen, Mignon van Os‐Medendorp, Harmieke van Dijk, Marijke R. Knol, Edward F. Knulst, André C. Röckmann, Heike Otten, Henny G. Systemic and local evidence for complement involvement in chronic spontaneous urticaria |
title | Systemic and local evidence for complement involvement in chronic spontaneous urticaria |
title_full | Systemic and local evidence for complement involvement in chronic spontaneous urticaria |
title_fullStr | Systemic and local evidence for complement involvement in chronic spontaneous urticaria |
title_full_unstemmed | Systemic and local evidence for complement involvement in chronic spontaneous urticaria |
title_short | Systemic and local evidence for complement involvement in chronic spontaneous urticaria |
title_sort | systemic and local evidence for complement involvement in chronic spontaneous urticaria |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254579/ https://www.ncbi.nlm.nih.gov/pubmed/34262691 http://dx.doi.org/10.1002/clt2.12011 |
work_keys_str_mv | AT alizadehaghdammehran systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria AT vandenelzenmignon systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria AT vanosmedendorpharmieke systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria AT vandijkmarijker systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria AT knoledwardf systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria AT knulstandrec systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria AT rockmannheike systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria AT ottenhennyg systemicandlocalevidenceforcomplementinvolvementinchronicspontaneousurticaria |